Searching for your content...
In-Language News
Contact Us
888-776-0942 from 8 AM - 10 PM ET
Nektar Therapeutics (Nasdaq: NKTR), a biotechnology company developing medicines for the treatment of auto-immune disorders, today announced the...
Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the fourth quarter and full year ended December 31, 2023. Cash and...
Nektar Therapeutics (Nasdaq: NKTR), a biotechnology company developing medicines for the treatment of auto-immune disorders, today announced that it...
Nektar Therapeutics (Nasdaq: NKTR) management is scheduled to present at the upcoming TD Cowen 44th Annual Health Care Conference in Boston on...
Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the fourth quarter and year-ended December 31, 2023 on Monday, March 4,...
Nektar (Nasdaq: NKTR) management is scheduled to present at the upcoming 42nd Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, ...
Nektar Therapeutics (NASDAQ:NKTR) announced that collaborators from the Cairo Laboratory at New York Medical College presented a poster highlighting...
Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the third quarter ended September 30, 2023. Cash and investments in...
Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter 2023 on Tuesday, November 7, 2023, after the close of...
Nektar Therapeutics (NASDAQ:NKTR) today announced new data for rezpegaldesleukin (REZPEG), a first-in-class selective regulatory T-cell (Treg)...
Nektar Therapeutics (NASDAQ:NKTR) announced today that it will have two presentations for rezpegaldesleukin (REZPEG), a first-in-class selective...
Nektar Therapeutics (Nasdaq: NKTR) announced today that it has entered into a new clinical study collaboration with Cellular Biomedicine Group Inc....
Nektar Therapeutics (Nasdaq: NKTR) today announced new data for rezpegaldesleukin in patients with atopic dermatitis, including new clinical efficacy ...
Nektar Therapeutics (Nasdaq: NKTR) today announced that it will host a virtual investor and analyst event on Wednesday, September 13, 2023 at 11:00 a....
Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the second quarter ended June 30, 2023. Cash and investments in marketable...
Nektar Therapeutics (Nasdaq: NKTR) today announced that efficacy data previously generated by Eli Lilly & Company for rezpegaldesleukin (REZPEG) that ...
Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the second quarter 2023 on Tuesday, August 8, 2023, after the close of U.S....
Nektar Therapeutics' (Nasdaq: NKTR) senior management is scheduled to participate in a virtual fireside chat at the upcoming Goldman Sachs 44th...
Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the first quarter ended March 31, 2023. Cash and investments in marketable...
Nektar Therapeutics (Nasdaq: NKTR) today announced that it will be regaining the full rights to REZPEG from Eli Lilly and Company. As announced in a...
-- Pipeline focus will prioritize programs in immunology, including REZPEG and several immunology research programs -- -- Development of NKTR-255 in...
Nektar Therapeutics (Nasdaq: NKTR) today issued a statement confirming that it does not have any accounts at Silicon Valley Bank, and it does not...
Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the fourth quarter and full year ended December 31, 2022. Cash and...
Nektar Therapeutics (Nasdaq: NKTR) today announced topline data from a Phase 2 randomized, double-blind, placebo-controlled study of...
Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard Robin, is scheduled to present at the upcoming 41st Annual J.P....
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.